---
title: 'Senior Director, Biostatistics at IMVT Corporation'
canonical: 'https://feeny.ai/job/senior-director-biostatistics-imvt-corporation-remote-swdw529e6zxr'
type: 'job'
last_seen: '2026-09-11'
---

# Senior Director, Biostatistics at IMVT Corporation

- **Company:** IMVT Corporation
- **Location:** Remote
- **Compensation:** $270k–$310k
- **Work type:** remote
- **Posted:** 2026-06-22
- **Last confirmed live:** 2026-09-11
- **Apply:** https://job-boards.greenhouse.io/imvtcorporation/jobs/6099135004

## Job description

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.

The Role:

The Senior Director, Biostatistics will serve as the Biostatistics lead for several Immunovant’s development programs. In this role, you will be collaborating with both internal and external stakeholders to deliver the tactical execution of our Biostatistics strategy. The individual in this position will have the unique opportunity to participate in the rapid growth of a biotech startup.

Key Responsibilities:

- Provide oversight and contributions to statistics strategy, planning, execution, and communication for programs as assigned.
- Provide scientifically rigorous statistical input into clinical development plans, protocol development, statistical analysis plans, regulatory submissions and questions, interpretation of statistical analysis results, and other product support initiatives.
- Develop effective collaborations with others within clinical teams and partner lines (such as Medical Directors and Regulatory).
- Ensure that all study and project level statistical activities are conducted in compliance with relevant regulatory requirements and Immunovant standards.
- Identify opportunities to utilize innovative statistical methodology to streamline the clinical development process and facilitate optimal decision-making.
- Manage indication/study biostatisticians.

Requirements:

- PhD. in Statistic, Biostatistics, Mathematics or related field
- 12+ years of experience in biotechnology, pharmaceutical or health related area
- Knowledge of relevant Health Authority and ICH guidelines, as well as regulations
- Demonstrated experience in engaging with Health Authorities
- Comprehensive understanding of drug development from Phase 2 to launch
- Demonstrated ability to collaborate with diverse sets of stakeholders
- Strong written and oral communication skills with attention to detail
- Desire to work in a fast-paced, innovative environment
- Natural collaborator who enjoys working on a cross-functional team

Work Environment:

- Remote-based
- Dynamic, interactive, fast-paced, and entrepreneurial environment
- Domestic or international travel are required (<10%)

Salary range for posting $270,000—$310,000 USD

Compensation is based on a number of factors, including market location, and may vary depending on job-related knowledge, skills, and experience. Equity and other forms of compensation may be provided as part of a total compensation package, in addition to a full range of medical, dental, vision, 401k, and other benefits, including unlimited paid time off and parental leave.

## About IMVT Corporation

## Company Overview
- **One-liner**: A clinical-stage immunology company developing innovative anti-FcRn therapies to enable normal lives for people with autoimmune diseases.
- **Entity Type**: Public (Nasdaq: IMVT)
- **Headquarters**: Durham, North Carolina, United States
- **Founded**: Not publicly available
- **Founders**: Not publicly available

## Core Business
- **Primary industry**: Biotechnology / Autoimmune disease therapeutics
- **Target customers**: Patients with IgG-mediated autoimmune diseases; healthcare providers; payers (B2B/B2C mix via prescription drugs)
- **Mission or purpose statement**: “Dedicated to enabling normal lives for people with autoimmune diseases” [immunovant.com](https://www.immunovant.com/)

## Products & Services
- **[IMVT-1402 (imeroprubart)]**: A novel, fully human monoclonal antibody that targets FcRn to reduce pathogenic IgG autoantibodies. Designed as a subcutaneous injection with a simple autoinjector (YpsoMate®). In clinical development for six indications: Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren’s disease (SjD), and cutaneous lupus erythematosus (CLE). [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)
- **[Batoclimab (first-generation anti-FcRn)]**: Development discontinued across all indications after Phase 3 TED trials did not meet primary endpoints; learnings inform IMVT-1402 program. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Market Standing
- **Valuation/Market Cap**: Not disclosed in available sources (publicly traded on Nasdaq; refer to real-time market data).
- **Key Metric**: Clinical-stage company with no approved products or revenue; total funding and operating expenses are detailed in SEC filings but not summarized here.
- **Notable Investors/Partners**: HanAll Biopharma (collaboration on anti-FcRn antibodies); Ypsomed AG (auto-injector YpsoMate®). [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)
- **Growth Signals**: Six ongoing clinical programs (including potentially registrational trials); deep IgG reductions (~80% with weekly 600 mg IMVT-1402) suggesting best-in-class potential; Phase 1 safety data showing no/minimal albumin reduction or LDL cholesterol increases. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Competitive Advantages
- **Potential best-in-class efficacy**: IMVT-1402 achieves deeper IgG reductions than competitor anti-FcRn antibodies, correlating with improved clinical outcomes.
- **Favorable safety profile**: No or minimal off-target effects on albumin and LDL cholesterol, unlike some FcRn inhibitors.
- **Convenient administration**: Self-administered subcutaneous autoinjector (YpsoMate®) expected at launch, improving patient adherence.
- **Broad pipeline**: Six indications in development across endocrinology, rheumatology, neurology, and dermatology, with potential for more.

## Strategic Focus
- Execute pivotal trials for IMVT-1402 in GD, D2T RA, MG, CIDP, SjD, and CLE.
- Leverage learnings from batoclimab program to accelerate IMVT-1402 development.
- Plan to assess new indications for IMVT-1402 beyond the initial six.
- Continue to build commercial capabilities for eventual launch. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Why Work Here
- **Culture**: Emphasizes “Hire and Retain Only the Very Best,” “One Team, Shared Success,” “Ownership Mentality,” and “Patients Are Waiting” – a mission-driven, high-performance environment. [About Us](https://www.immunovant.com/about-us)
- **Remote/Hybrid Policy**: Job listings show a mix of remote and hybrid roles (e.g., “Remote” for many positions, “Hybrid - NYC” for commercial roles). [Careers](https://www.immunovant.com/join-us/explore-careers)
- **Notable Perks**: Merit-based recognition, focus on impact and results, creative problem-solving encouraged. [About Us](https://www.immunovant.com/about-us)
- **Engineering/Science Culture**: Clinical-stage biotech with cutting-edge FcRn technology; opportunities in clinical development, biometrics, quality assurance, and commercial roles. [Careers](https://www.immunovant.com/join-us/explore-careers)

## Sources
1. [Immunovant Corporate Website](https://www.immunovant.com/)
2. [About Us – Values and Culture](https://www.immunovant.com/about-us)
3. [Company Information – Investor Relations](https://www.immunovant.com/investors/company-information)
4. [Explore Careers – Job Listings](https://www.immunovant.com/join-us/explore-careers)
5. [10-K SEC Filing (May 20, 2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Other roles at IMVT Corporation

- [Senior Director, Data Management Systems](https://feeny.ai/job/senior-director-data-management-systems-imvt-corporation-remote-bw7zc2r5bz1x)
- [Associate Director, Supply Chain Product Planning](https://feeny.ai/job/associate-director-supply-chain-product-planning-imvt-corporation-remote-xhnnchmc99f3)
- [Executive Assistant](https://feeny.ai/job/executive-assistant-imvt-corporation-new-york-m7dv0wr8rkjs) — New York, NY
- [Senior Manager, QC](https://feeny.ai/job/senior-manager-qc-imvt-corporation-remote-a2g9683h4zsg)
- [Director, Medical Science Liaison (MSL)](https://feeny.ai/job/director-medical-science-liaison-msl-imvt-corporation-southeast-cnykwbftkpjw) — Southeast
- [Director, Marketing](https://feeny.ai/job/director-marketing-imvt-corporation-remote-4t6kt28mgdh0)
- [Senior Director, Biostatistics](https://feeny.ai/job/senior-director-biostatistics-spyre-therapeutics-united-states-ehz60g8kxfxv) — United States